ArticleCureus2025
Survival Outcomes in Bladder Cancer: An Ambispective Study of Patients Undergoing Radical Cystectomy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Radical cystectomy (RC) with pelvic lymph node dissection and urinary diversion is the preferred treatment for non-metastatic muscle invasive bladder cancer (MIBC) and for some high-risk non-muscle invasive bladder cancer (NMIBC), in patients fit for major surgery. Primary objective The primary objective of this study is to estimate the overall survival (OS) of patients with MIBC who have undergone RC. Secondary objective The secondary objectives are to estimate the disease-free survival (DFS) of patients with MIBC following RC and to determine factors that influence OS and DFS in this population. Methodology This was an ambispective study of patients who underwent RC for carcinoma of the urinary bladder between 1st January 2010 and 30th April 2022. Clinicopathological data were obtained from the patients' clinical records. Results The study included a total of 106 patients, with a mean age of 59.35 years. Of these, 55.88% had received neoadjuvant chemotherapy (NACT), and 13 patients (11.7%) underwent salvage cystectomy. Only five patients received intravesical chemotherapy instillation following transurethral resection of bladder tumor (TURBT). RC was performed via laparotomy in 82 patients, while 24 patients underwent a laparoscopic approach. The mean hospital stay was five days. Ninety-eight patients had Clavien-Dindo grade II morbidity. There were no intra-hospital or 30-day mortalities. The histopathologic report showed that 21 patients had achieved pathological complete response (PCR). A total of 96 patients were kept on follow-up, of whom 32 patients had recurrence. Median DFS was 145 months, and median OS was 118 months. PCR was found to be significantly associated with improved DFS. Smoking was found to be a significant predictor of OS on multivariate analysis. Conclusions Although NACT did not reach statistical significance as an independent predictor of survival, it contributed to the achievement of PCR, which was predictive of DFS and OS. Hence, NACT should be pursued wherever feasible. Further, this study shows the importance of smoking cessation, as current or recent smoking was found to have a negative impact on survival among patients with bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.